This book deals with predominantly synthetic chemical approaches to drug design and explores the use of structure-activity relationships in the design of novel inhibitors of ribonucleotide reductase. It describes the application of the tools of structural biology to pharmaceutical development.

This book is the first to provide both a broad overview of the current methodologies being applied to drug design and in-depth analyses of progress in specific fields. It details state-of-the-art approaches to pharmaceutical development currently used by some of the world's foremost laboratories. The book features contributors from a variety of fields, new techniques, previously unpublished data, and extensive reference lists.